source
- Slate Medicines secures $245M financing and Nasdaq listing via reverse merger with Fulcrum TherapeuticsSlate Medicines, a North Carolina biotech, is moving toward a Nasdaq listing through a reverse merger with Fulcrum Therapeutics, six months after emerging from stealth. The transaction includes a…
- Sanofi to cut 229 Massachusetts jobs a year after $9.1 billion Blueprint Medicines acquisitionSanofi announced it will lay off 229 employees in Massachusetts, according to a filing with the state's Executive Office of Labor and Workforce Development. The workers are from Blueprint Medicine…